Zero Ischemia Robot-Assisted Microwave Ablation Assisted Suture-less Enucleation of Renal Cell Carcinoma With T1 Stage: A Randomized Clinical Trial

What this Trial Is About

Researchers are evaluating a new surgical technique called zero ischemia robot-assisted microwave ablation assisted suture-less tumor enucleation for patients with T1 stage renal cell carcinoma (RCC). This study builds on previous findings where the laparoscopic version of this technique showed better preservation of kidney function compared to conventional laparoscopic partial nephrectomy. The goal is to adapt this approach to robotic surgery, adding suture-less methods and using real-time contrast-enhanced ultrasonography to improve safety and precision. The study compares two groups of patients with T1 stage RCC: one group undergoes the zero ischemia robot-assisted microwave ablation and suture-less tumor enucleation, while the other group has traditional robotic-assisted partial nephrectomy. During the experimental procedure, a microwave ablation probe is inserted into the tumor under ultrasound guidance, with controlled ablation cycles to minimize bleeding. The tumor is then carefully separated from the kidney without clamping the renal artery, and suturing is done only if needed to repair the urinary collecting system. Participants will be followed for at least 12 months after surgery with various assessments including measurements of kidney function through glomerular filtration rate (GFR) and estimated GFR (eGFR), blood loss during surgery, surgical margins, postoperative complications, recurrence rates, and hospital stay duration. The study includes baseline, 3-month, and 12-month evaluations to monitor kidney function and other outcomes. This monitoring aims to understand the impact of the new surgical technique on kidney preservation and patient recovery.

Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage